Page 19 - அல்லாத சிறிய செல் நுரையீரல் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical . OSE ImmunotherapeuticsMarch 15, 2021 GMT This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and OSE Immunotherapeutics. The study will explore Tedopi®’s potential in an additional oncology indication with significant unmet medical need. NANTES, France, March 15, 2021 (GLOBE NEWSWIRE) OSE Immunotherapeutics (FR0012127173) and the French cooperative group ARCAGY-GINECO today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethic Committee (CPP) approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in patients with recurrent ovarian cancer (the TED

United statesAlexis peyrolesMerck keytrudaGustave roussyAlexandra learyHealth products safetyFrench cooperative group in oncologyFrench national agency for medicinesBoehringer ingelheimMerck co incEuropean society of gynecological oncologyEuropean network for gynecological oncological trialEuropean network for gynaecological trial groupsInvestigateurs nationalMerck sharp dohme corpFrench central ethic committee